Please select the option that best describes you:
How do you choose among regimens for relapsed refractory myeloma?
Specifically, to you lean towards elotuzumab or a daratumumab-based regimen?
Answer from: Medical Oncologist at Community Practice
To be brief - no one chooses elotuzumab with no single agent activity if Daratumumab is available, with its approximate 30% response rate in its pivotal study. I was just sitting down at a meeting with a number of myeloma physicians asking how do we currently choose treatment for relapsed myeloma.F...
Sign In or Register to read more